CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Zero-based budgeting methodology requires justification for every expense, while traditional budgeting uses historical spending as a baseline.
19,457 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
United Natural Foods stock dropped after the latest earnings release, signaling a mix of revenue challenges and margi...
A growing number of families face a tight budget as memory-care costs push toward $95,000 per year for private facili...
Markets brace for Kevin Warsh’s first policy meeting as chair, with expectations for a steady rate path and close att...
AI-led gains cool as a quintet of warning signs reappear, drawing parallels to the late-2000s Nasdaq run. Investors b...
A bold IPO from Quantinuum has lit a new phase for quantum stocks. As quantinuum's putting pressure ionq, investors n...
Imagine a future where spacex worth more than Amazon becomes market reality. This article lays out the drivers, scena...
In mid-June, hawkish central bank signals set the tone for global markets. The FTSE 100 faltered while the Nikkei 225...
Urban air taxis are moving from concept to reality. This article explores Joby Aviation, the eVTOL pioneer, and wheth...
As ad-tech rotates from pandemic-driven momentum to more measured growth, The Trade Desk faces a pivotal moment. This...
Investors are pouring capital into a new class of AI startups focused on world models, a movement led by tech founder...
New York City Mayor Zohran Mamdani engineered a sweeping primary win, elevating a progressive slate and exposing a cr...